NHS National Framework for Transition products commencing 1 October 2024
Who
| Buyer | NHS England — not a council we hold |
| Supplier | Accord-UK Ltd |
| Supplier | Amarox Limited |
| Supplier | Celix Pharma Ltd. |
| Supplier | Dr.Reddy's Laboratories (UK) Limited |
| Supplier | Gilead Sciences Limited |
| Supplier | Glenmark Pharmaceuticals Europe Limited |
| Supplier | Mercury Pharmaceuticals Limited |
| Supplier | Seacross Pharmaceuticals Ltd |
| Supplier | Teva UK Limited |
| Supplier | Thornton and Ross Ltd |
| Supplier | Tillomed Laboratories ltd |
| Supplier | Zentiva Pharma UK Ltd |
What
Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Dates and source
| Runs | 1 Oct 2024 to 31 May 2026 |
| OCID | ocds-b5fd17-fb0aeb89-2056-4b82-a415-3842e6b7e9c0 |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.